{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T08:21:47Z","timestamp":1768465307847,"version":"3.49.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1124\/jpet.115.229906","type":"journal-article","created":{"date-parts":[[2015,12,24]],"date-time":"2015-12-24T04:05:42Z","timestamp":1450929942000},"page":"604-614","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["ASB14780, an Orally Active Inhibitor of Group IVA Phospholipase A2, Is a Pharmacotherapeutic Candidate for Nonalcoholic Fatty Liver Disease"],"prefix":"10.1016","volume":"356","author":[{"given":"Shiho","family":"Kanai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8748-7218","authenticated-orcid":false,"given":"Keiichi","family":"Ishihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eri","family":"Kawashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Tomoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Nagahira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Akiba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.115.229906_bib1","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1053\/j.gastro.2008.06.047","article-title":"Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis","volume":"135","author":"Aithal","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1124\/jpet.115.229906_bib2","doi-asserted-by":"crossref","unstructured":"Angelico F, Burattin M, Alessandri C, Del Ben M, Lirussi F (2007) Drugs improving insulin resistance for non-alcoholic fatty liver disease and\/or non-alcoholic steatohepatitis. Cochrane Database Syst Rev (1):CD005166.","DOI":"10.1002\/14651858.CD005166.pub2"},{"key":"10.1124\/jpet.115.229906_bib3","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1056\/NEJMra011775","article-title":"Nonalcoholic fatty liver disease","volume":"346","author":"Angulo","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.115.229906_bib4","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.tox.2006.09.019","article-title":"A temporal study on the histopathological, biochemical and molecular responses of CCl(4)-induced hepatotoxicity in Cyp2e1-null mice","volume":"228","author":"Avasarala","year":"2006","journal-title":"Toxicology"},{"key":"10.1124\/jpet.115.229906_bib5","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1172\/JCI24282","article-title":"Liver fibrosis","volume":"115","author":"Bataller","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1124\/jpet.115.229906_bib6","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa060326","article-title":"A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis","volume":"355","author":"Belfort","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.115.229906_bib7","first-page":"127","article-title":"Spectrophotometric analysis of human CYP2E1-catalyzed p-nitrophenol hydroxylation","volume":"320","author":"Chang","year":"2006","journal-title":"Methods Mol Biol"},{"issue":"Suppl 1","key":"10.1124\/jpet.115.229906_bib8","first-page":"S5","article-title":"The epidemiology of nonalcoholic fatty liver disease in adults","volume":"40","author":"Clark","year":"2006","journal-title":"J Clin Gastroenterol"},{"key":"10.1124\/jpet.115.229906_bib9","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1002\/hep.23813","article-title":"Tamoxifen induces triacylglycerol accumulation in the mouse liver by activation of fatty acid synthesis","volume":"52","author":"Cole","year":"2010","journal-title":"Hepatology"},{"key":"10.1124\/jpet.115.229906_bib10","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1021\/jm011050x","article-title":"Design and synthesis of a novel and potent series of inhibitors of cytosolic phospholipase A(2) based on a 1,3-disubstituted propan-2-one skeleton","volume":"45","author":"Connolly","year":"2002","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.115.229906_bib11","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jhep.2004.01.009","article-title":"Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis","volume":"40","author":"Czaja","year":"2004","journal-title":"J Hepatol"},{"key":"10.1124\/jpet.115.229906_bib12","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/sj.bjp.0706879","article-title":"Effects of pyrrophenone, an inhibitor of group IVA phospholipase A2, on eicosanoid and PAF biosynthesis in human neutrophils","volume":"149","author":"Flamand","year":"2006","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.115.229906_bib13","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0021-9258(18)64849-5","article-title":"A simple method for the isolation and purification of total lipides from animal tissues","volume":"226","author":"Folch","year":"1957","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.115.229906_bib14","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1016\/j.bmc.2008.02.019","article-title":"1-(2-Carboxyindol-5-yloxy)propan-2-ones as inhibitors of human cytosolic phospholipase A2\u03b1: synthesis, biological activity, metabolic stability, and solubility","volume":"16","author":"Fritsche","year":"2008","journal-title":"Bioorg Med Chem"},{"key":"10.1124\/jpet.115.229906_bib15","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1194\/jlr.M600148-JLR200","article-title":"Causes and prevention of tamoxifen-induced accumulation of triacylglycerol in rat liver","volume":"47","author":"Gudbrandsen","year":"2006","journal-title":"J Lipid Res"},{"key":"10.1124\/jpet.115.229906_bib16","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1016\/j.bmc.2007.02.016","article-title":"1-(5-Carboxy- and 5-carbamoylindol-1-yl)propan-2-ones as inhibitors of human cytosolic phospholipase A2\u03b1: bioisosteric replacement of the carboxylic acid and carboxamide moiety","volume":"15","author":"Hess","year":"2007","journal-title":"Bioorg Med Chem"},{"key":"10.1124\/jpet.115.229906_bib17","doi-asserted-by":"crossref","first-page":"e8089","DOI":"10.1371\/journal.pone.0008089","article-title":"Alleviation of high-fat diet-induced fatty liver damage in group IVA phospholipase A2-knockout mice","volume":"4","author":"Ii","year":"2009","journal-title":"PLoS One"},{"key":"10.1124\/jpet.115.229906_bib18","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.1096\/fj.12-205625","article-title":"Group IVA phospholipase A2 participates in the progression of hepatic fibrosis","volume":"26","author":"Ishihara","year":"2012","journal-title":"FASEB J"},{"key":"10.1124\/jpet.115.229906_bib19","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0021-9258(18)48461-X","article-title":"Free fatty acid transfer from rat liver fatty acid-binding protein to phospholipid vesicles. Effect of ligand and solution properties","volume":"267","author":"Kim","year":"1992","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.115.229906_bib20","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.bbalip.2006.08.001","article-title":"Biochemical properties and pathophysiological roles of cytosolic phospholipase A2s","volume":"1761","author":"Kita","year":"2006","journal-title":"Biochim Biophys Acta"},{"key":"10.1124\/jpet.115.229906_bib21","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"10.1124\/jpet.115.229906_bib22","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1021\/jm025538p","article-title":"Novel 2-oxoamide inhibitors of human group IVA phospholipase A(2)","volume":"45","author":"Kokotos","year":"2002","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.115.229906_bib23","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1021\/jm030485c","article-title":"Inhibition of group IVA cytosolic phospholipase A2 by novel 2-oxoamides in vitro, in cells, and in vivo","volume":"47","author":"Kokotos","year":"2004","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.115.229906_bib24","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S0168-8278(01)00218-5","article-title":"Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B","volume":"35","author":"Kweon","year":"2001","journal-title":"J Hepatol"},{"key":"10.1124\/jpet.115.229906_bib25","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S0140-6736(07)61514-1","article-title":"Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials","volume":"370","author":"Lago","year":"2007","journal-title":"Lancet"},{"key":"10.1124\/jpet.115.229906_bib26","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s11914-010-0027-y","article-title":"Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis","volume":"8","author":"Lecka-Czernik","year":"2010","journal-title":"Curr Osteoporos Rep"},{"key":"10.1124\/jpet.115.229906_bib27","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1021\/jm061131z","article-title":"Discovery of Ecopladib, an indole inhibitor of cytosolic phospholipase A2\u03b1","volume":"50","author":"Lee","year":"2007","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.115.229906_bib28","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.toxlet.2010.10.008","article-title":"Gene expression profiling of murine hepatic steatosis induced by tamoxifen","volume":"199","author":"Lee","year":"2010","journal-title":"Toxicol Lett"},{"key":"10.1124\/jpet.115.229906_bib29","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1096\/fj.04-3196com","article-title":"Transcript and metabolite analysis of the effects of tamoxifen in rat liver reveals inhibition of fatty acid synthesis in the presence of hepatic steatosis","volume":"19","author":"Lelliott","year":"2005","journal-title":"FASEB J"},{"key":"10.1124\/jpet.115.229906_bib30","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.jhep.2011.03.017","article-title":"Cytosolic phospholipase A(2)\u03b1 protects against Fas- but not LPS-induced liver injury","volume":"55","author":"Li","year":"2011","journal-title":"J Hepatol"},{"key":"10.1124\/jpet.115.229906_bib31","doi-asserted-by":"crossref","unstructured":"Lirussi F, Azzalini L, Orando S, Orlando R, Angelico F (2007) Antioxidant supplements for non-alcoholic fatty liver disease and\/or steatohepatitis. Cochrane Database Syst Rev (1):CD004996.","DOI":"10.1002\/14651858.CD004996.pub3"},{"key":"10.1124\/jpet.115.229906_bib32","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1021\/jm051243a","article-title":"Design and synthesis of 1-indol-1-yl-propan-2-ones as inhibitors of human cytosolic phospholipase A2\u03b1","volume":"49","author":"Ludwig","year":"2006","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.115.229906_bib33","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1053\/jhep.2002.31551","article-title":"NASH: from liver diseases to metabolic disorders and back to clinical hepatology","volume":"35","author":"Marchesini","year":"2002","journal-title":"Hepatology"},{"issue":"11, Suppl 1","key":"10.1124\/jpet.115.229906_bib34","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1210\/jc.2008-1399","article-title":"Obesity-associated liver disease","volume":"93","author":"Marchesini","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1124\/jpet.115.229906_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1432-1033.1997.00001.x","article-title":"The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis","volume":"244","author":"McGarry","year":"1997","journal-title":"Eur J Biochem"},{"key":"10.1124\/jpet.115.229906_bib36","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1021\/jm0507882","article-title":"Inhibition of cytosolic phospholipase A2\u03b1: hit to lead optimization","volume":"49","author":"McKew","year":"2006","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.115.229906_bib37","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1021\/jm701467e","article-title":"Indole cytosolic phospholipase A2 \u03b1 inhibitors: discovery and in vitro and in vivo characterization of 4-3-[5-chloro-2-(2-[(3,4-dichlorobenzyl)sulfonyl]aminoethyl)-1-(diphenylmethyl)-1H-indol-3-yl]propylbenzoic acid, efipladib","volume":"51","author":"McKew","year":"2008","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.115.229906_bib38","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1016\/j.bmcl.2003.08.070","article-title":"Structure-activity relationships of indole cytosolic phospholipase A(2)\u03b1 inhibitors: substrate mimetics","volume":"13","author":"McKew","year":"2003","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1124\/jpet.115.229906_bib39","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/hep.23623","article-title":"A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease","volume":"52","author":"Musso","year":"2010","journal-title":"Hepatology"},{"key":"10.1124\/jpet.115.229906_bib40","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/0006-2952(82)90440-3","article-title":"Specificity of a phenobarbital-induced cytochrome P-450 for metabolism of carbon tetrachloride to the trichloromethyl radical","volume":"31","author":"Noguchi","year":"1982","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/jpet.115.229906_bib41","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1042\/bj3630727","article-title":"Characterization of a novel inhibitor of cytosolic phospholipase A2\u03b1, pyrrophenone","volume":"363","author":"Ono","year":"2002","journal-title":"Biochem J"},{"key":"10.1124\/jpet.115.229906_bib42","doi-asserted-by":"crossref","unstructured":"Orlando R, Azzalini L, Orando S, Lirussi F (2007) Bile acids for non-alcoholic fatty liver disease and\/or steatohepatitis. Cochrane Database Syst Rev (1):CD005160.","DOI":"10.1002\/14651858.CD005160.pub2"},{"key":"10.1124\/jpet.115.229906_bib43","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/S0891-5849(02)00970-X","article-title":"Rosmarinic acid, a major polyphenolic component of Perilla frutescens, reduces lipopolysaccharide (LPS)-induced liver injury in D-galactosamine (D-GalN)-sensitized mice","volume":"33","author":"Osakabe","year":"2002","journal-title":"Free Radic Biol Med"},{"key":"10.1124\/jpet.115.229906_bib44","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.2337\/dc10-2412","article-title":"Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting","volume":"34","author":"Piccinni","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1124\/jpet.115.229906_bib45","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1053\/j.gastro.2004.04.062","article-title":"Immune stimulation of hepatic fibrogenesis by CD8 cells and attenuation by transgenic interleukin-10 from hepatocytes","volume":"127","author":"Safadi","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1124\/jpet.115.229906_bib46","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.115.229906_bib47","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1021\/jm9905155","article-title":"Pyrrolidine inhibitors of human cytosolic phospholipase A(2)","volume":"43","author":"Seno","year":"2000","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.115.229906_bib48","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S0960-894X(01)00003-8","article-title":"Pyrrolidine inhibitors of human cytosolic phospholipase A2. Part 2: synthesis of potent and crystallized 4-triphenylmethylthio derivative \u2018pyrrophenone\u2019","volume":"11","author":"Seno","year":"2001","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1124\/jpet.115.229906_bib49","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1021\/jm0613673","article-title":"Structure-activity relationship of 2-oxoamide inhibition of group IVA cytosolic phospholipase A2 and group V secreted phospholipase A2","volume":"50","author":"Six","year":"2007","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.115.229906_bib50","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1021\/jm050993h","article-title":"Differential inhibition of group IVA and group VIA phospholipases A2 by 2-oxoamides","volume":"49","author":"Stephens","year":"2006","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.115.229906_bib51","doi-asserted-by":"crossref","first-page":"7352","DOI":"10.3390\/ijms15057352","article-title":"Molecular mechanisms and new treatment strategies for non-alcoholic steatohepatitis (NASH)","volume":"15","author":"Takaki","year":"2014","journal-title":"Int J Mol Sci"},{"key":"10.1124\/jpet.115.229906_bib52","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1159\/000282083","article-title":"The role of cytokines in non-alcoholic fatty liver disease","volume":"28","author":"Tilg","year":"2010","journal-title":"Dig Dis"},{"key":"10.1124\/jpet.115.229906_bib53","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1002\/hep.24001","article-title":"Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis","volume":"52","author":"Tilg","year":"2010","journal-title":"Hepatology"},{"key":"10.1124\/jpet.115.229906_bib54","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/j.1365-2036.2004.01881.x","article-title":"Review article: current management of alcoholic liver disease","volume":"19","author":"Tome","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1124\/jpet.115.229906_bib55","doi-asserted-by":"crossref","first-page":"7244","DOI":"10.1021\/jm500494y","article-title":"Design, synthesis, and biological evaluation of 3-(1-Aryl-1H-indol-5-yl)propanoic acids as new indole-based cytosolic phospholipase A2\u03b1 inhibitors","volume":"57","author":"Tomoo","year":"2014","journal-title":"J Med Chem"},{"issue":"Suppl 1","key":"10.1124\/jpet.115.229906_bib56","first-page":"S50","article-title":"Roles of oxidative stress in activation of Kupffer and Ito cells in liver fibrogenesis","volume":"10","author":"Tsukamoto","year":"1995","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1124\/jpet.115.229906_bib57","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1002\/hep.24544","article-title":"Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial","volume":"54","author":"Zein","year":"2011","journal-title":"Hepatology"},{"key":"10.1124\/jpet.115.229906_bib58","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0014-4800(88)90023-8","article-title":"Proliferation of fat-storing cells is stimulated by secretions of Kupffer cells from normal and injured liver","volume":"49","author":"Zerbe","year":"1988","journal-title":"Exp Mol Pathol"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524192580?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524192580?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.115.229906","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T19:42:59Z","timestamp":1739994179000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524192580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":58,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["S0022356524192580"],"URL":"https:\/\/doi.org\/10.1124\/jpet.115.229906","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ASB14780, an Orally Active Inhibitor of Group IVA Phospholipase A2, Is a Pharmacotherapeutic Candidate for Nonalcoholic Fatty Liver Disease","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.115.229906","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}